New oral anticoagulants in surgery

Jihane Abou Rahal, Zaher K. Otrock, Joseph E. Maakaron, Ali Taher

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

For over 50 years, the only available oral anticoagulants for the treatment and prevention of thromboembolic diseases have been vitamin K antagonists (VKA) such as warfarin. Although highly effective, VKAs have many disadvantages: they have a narrow therapeutic range with a subsequent need for frequent monitoring, a >10-fold interindividual variation in dose-response, and numerous interactions with drugs and food. Thus, antithrombotics have been developed, and they emerged to circumvent these problems and limitations.

Original languageEnglish (US)
Title of host publicationVascular Surgery
PublisherSpringer London
Pages331-338
Number of pages8
ISBN (Electronic)9781447129127
ISBN (Print)9781447129110
DOIs
StatePublished - Jan 1 2012
Externally publishedYes

Keywords

  • Apixaban
  • Dabigatran
  • Oral anticoagulants
  • Rivaroxaban
  • Venous thromboembolic disease

Fingerprint

Dive into the research topics of 'New oral anticoagulants in surgery'. Together they form a unique fingerprint.

Cite this